Business
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Hepatitis B virus e antigen positive (HBeAg+) subjects dosed with once-daily 300mg ALG-000184 + entecavir for up to 48 weeks demonstrated: Dose dependent mean
About this update from Aligos Therapeutics, Inc.
[{"type":"text","content":"Hepatitis B virus e antigen positive (HBeAg+) subjects dosed with once-daily 300mg ALG-000184 + entecavir for up to 48 weeks demonstrated: Dose dependent mean reductions of up to 2 log10 IU/mL for HBV antigensMean DNA reductions of up to 6.8 log10 IU/mL No viral DNA breakthroughs in subjects receiving ALG-000184 monotherapyData suggest ALG-000184 may lower cccDNA levels via both mechanisms of action for CAM-E drugsA well tolerated safety profile SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that emerging hepatitis B antigen lowering data for its capsid assembly modulator – empty (CAM-E) drug, ALG-000184, are available as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023. Poster (#5028-C), “Long-term dosing with the capsid assembly modulator ALG-000184 results in multi-log reductions of DNA, RNA, HBsAg, HBeAg, and HBcrAg in untreated HBeAg positive chronic hepatitis B subjects,” is now accessible at The Liver Meeting® and on the “Scientific Presentations & Conferences” section of the Aligos website (www.aligos.com). The data will be presented by Dr. Man-Fung Yuen, Chair and Professor of Gastroenterology and Hepatology at the University of Hong Kong, in Poster Hall C on Monday November 13 from 1-2 pm ET. Important highlights from the poster, which summarizes safety and antiviral activity data in HBeAg positive subjects receiving once-daily 300 mg ALG-000184 + entecavir (ETV) x ≤48 weeks, include: Mean HBsAg, HBeAg, and HBcrAg reductions of 1.2 log10 IU/mL, 1.7 log10 PEI U/L and 2.0 log10 U/mL, respectively, at Week 48. These reductions were dose-dependent, independent of co-administration of ETV, and suggest that ALG-000184 may reduce cccDNA levels via both the 1st and 2nd mechanisms of action of CAM-E drugsGreater mean DNA reductions were observed for ALG-000184 + ETV vs. ETV monotherapy after treatment for 12 weeks; maximum mean DNA reductions of 6.8 log10 IU/mL for the ALG-000184 + ETV combination were observed at Week 48Mean DNA reductions were comparable for 300 mg ALG-000184 with or witho...